Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

LSE:IMM Surges More Than 7% as Investors Eye the Next Healthcare Growth Opportunity

•LSE:IMMadvanced approximately7.74%during trading on21 July 2026, emerging among the strongest-performing UK healthcare shares.

Ankur Sharma | 21 July 2026

Can SkinBioTherapeutics Plc Sustain Its Position in Healthcare & Biotech?

Companies in the healthcare & biotech space are typically valued using metrics relevant to their business model and sector peers.

Ishan Mudgal | 21 July 2026

Can EDX Medical Group PLC Sustain Its Position in Healthcare & Diagnostics?

Companies in the healthcare & diagnostics space are typically valued using metrics relevant to their business model and sector peers.

Ishan Mudgal | 21 July 2026

MedPal AI (LSE:MPAL): Could Artificial Intelligence Transform This Emerging Healthcare Company?

MedPal AI plc (LSE:MPAL) is a London-based digital health company that joined the AIM market of the London Stock Exchange in August 2025. Its founding proposition was consumer-first and deliberately non-clinical: a smartphone application that aggregates and monitors a user's health metrics and offers …

Ankur Sharma | 21 July 2026

Sareum Holdings (LSE:SAR): Could Its TYK2 Pipeline Become a Biotech Breakthrough?

Sareum Holdings plc (LSE:SAR) is a United Kingdom drug discovery company quoted on London's AIM market and based in Cambridge. It specialises in small-molecule kinase inhibitors, an area of drug design targeting the enzymes that drive many diseases, and has built its pipeline around …

Ankur Sharma | 21 July 2026

Avacta Group (LSE:AVCT): Could Its Precision-Oncology Pipeline Redefine the Investment Case?

Avacta Group (LSE:AVCT) is a British clinical-stage biotechnology company that has spent the past eighteen months transforming from a diversified life-sciences group into a focused precision-oncology developer. Historically the business combined a therapeutics arm with a profitable diagnostics division, but management concluded the two …

Ankur Sharma | 21 July 2026

ImmuPharma (LSE:IMM): Could the Next Clinical Milestone Transform Its Biotech Story?

ImmuPharma Plc, listed on London's AIM market under the ticker IMM, is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, with a long-standing focus on autoimmune disease. Its defining asset is P140, a synthetic peptide historically branded Lupuzor and described as a …

Ankur Sharma | 21 July 2026

ECO Animal Health (EAH): FY2026 Results Beat Expectations as North America and Vaccines Drive Growth

ECO Animal Health Group plc is a London-headquartered developer and marketer of medicines for farmed animals, quoted on London's AIM market under the ticker EAH. Its business has historically centred on Aivlosin, a macrolide antibiotic based on the active ingredient tylvalosin, used to treat …

Ankur Sharma | 21 July 2026

Sareum Holdings (SAR): SDC-1801 Phase 1 Data Published as TYK2/JAK1 Inhibitor Nears a Phase 2 Decision

Sareum Holdings plc (LSE:SAR) is a small UK drug-discovery company developing selective kinase inhibitors for autoimmune, inflammatory and cancer indications. Its lead asset is SDC-1801, an oral small molecule designed to inhibit two enzymes, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). These …

Ankur Sharma | 21 July 2026

Can Diagnostic Testing Drive Bioventix's Future Growth?

As of 21 July 2026, Bioventix PLC (LSE:BVXP) shares were down2.58%, making the biotechnology company one of the notable decliners on the London market today. Despite the weakness, there wasno material company-specific regulatory announcementreleased during the trading session that directly explained the decline. The …

Divya Sood | 21 July 2026
Support

Hi! How can we help you today?

Loading…